First series of 18 pregnancies after ulipristal acetate treatment for uterine fibroids

The first series of pregnancies achieved after UPA treatment is reported.

Like Comment

Authors

Mathieu Luyckx, M.D., Jean-Luc Squifflet, M.D., Ph.D., Pascale Jadoul, M.D., Rafaella Votino, M.D., Marie-Madeleine Dolmans, M.D., Ph.D., Jacques Donnez, M.D., Ph.D.

Volume 102, Issue 5, Pages 1404–1409

Abstract

Objective:

To study the pregnancy rate after ulipristal acetate (UPA) therapy for fibroids.

Design:

Retrospective analysis of a series of 52 patients prospectively included in the PGL4001 (ulipristal acetate) Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata (PEARL) II and III trials.

Setting:

Academic hospital.

Patient(s):

Among the 52 patients, 21 wished to conceive upon treatment completion.

Intervention(s):

None.

Main Outcome Measure(s):

Pregnancy rate and live birth rate.

Result(s):

Twenty-one patients attempted to get pregnant, among whom 15 (71%) succeeded, totaling 18 pregnancies. Among these 18 pregnancies, 12 resulted in the birth of 13 healthy babies and 6 ended in early miscarriage. No regrowth of fibroids was observed during pregnancy.

Conclusion(s):

We report the first series of pregnancies achieved after UPA treatment. Our data confirm a sustained long-term effect after UPA therapy.

Read the full text at: http://www.fertstert.org/article/S0015-0282(14)02024-X/fulltext


Go to the profile of Fertility and Sterility

Fertility and Sterility

Editorial Office, American Society for Reproductive Medicine

Fertility and Sterility® is an international journal for obstetricians, gynecologists, reproductive endocrinologists, urologists, basic scientists and others who treat and investigate problems of infertility and human reproductive disorders. The journal publishes juried original scientific articles in clinical and laboratory research relevant to reproductive endocrinology, urology, andrology, physiology, immunology, genetics, contraception, and menopause. Fertility and Sterility® encourages and supports meaningful basic and clinical research, and facilitates and promotes excellence in professional education, in the field of reproductive medicine.

No comments yet.